BeiGene
BGNE
#882
Rank
NZ$38.53 B
Marketcap
$344.39
Share price
-0.65%
Change (1 day)
1.82%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$27.43

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$27.89. In 2022 the company made an earnings per share (EPS) of -$32.47 a decrease over its 2021 EPS that were of -$25.49.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$27.43-15.51%
2022-$32.4727.35%
2021-$25.49-19.96%
2020-$31.8520.81%
2019-$26.3731.52%
2018-$20.05417.57%
2017-$3.87-37.16%
2016-$6.16158.95%
2015-$2.38

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.68-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.45-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA